Netflix Star Yuri Nakamura Dies at 44 After Rectal Cancer Recurrence and Metastasis

Japanese-Korean actress Yuri Nakamura, known internationally for Netflix’s Romantics Anonymous, has died at the age of 44 from rectal cancer. Her agency, Alpha Agency, announced on September 14, 2026, that Nakamura had died on September 1. A private funeral was held with family members, actors from her agency, and staff. Nakamura had lived privately with cancer for years while continuing an acting career spanning television and film. Her death also draws attention to rectal cancer, metastatic disease, cancer recurrence, and the increasing incidence of colorectal cancer among younger adults.

Photo: @yurinakamurawoori Instagram account

Yuri Nakamura’s Cancer Timeline

According to her agency, Nakamura had previously been diagnosed with cancer approximately 13 years before her death. The specific type of that first cancer was not publicly disclosed. She subsequently entered remission, continued acting, and reportedly underwent regular medical examinations. In January 2025, cancer was detected again.

Nakamura underwent surgery, which her agency described as successful, but metastases were identified afterward. At that point, the agency said achieving cure or another remission was considered difficult, and she continued receiving treatment aimed at living as fully and for as long as possible while working when her health allowed. In July 2026, she withdrew from an upcoming television production after developing an intestinal obstruction. In August, she experienced another bowel obstruction and was informed that her remaining time could be limited. She died on September 1 surrounded by people close to her.

Importantly, although Nakamura ultimately died from rectal cancer, her agency has not publicly identified the type of cancer she experienced approximately 13 years earlier. It therefore cannot be stated with certainty that her later rectal cancer represented a recurrence of that original disease.

From Japan to Netflix: Yuri Nakamura’s Acting Career

Yuri Nakamura built an acting career spanning more than two decades after first entering Japan’s entertainment industry through music in the late 1990s. She later transitioned to television and film, earning recognition for roles in productions including Pacchigi! Love & Peace, Like Father, Like Son, After the Storm, Fukushima 50, and Beyond Goodbye.

Her international profile grew further with Netflix’s Romantics Anonymous, released in 2025, in which she played Irene, a therapist and one of the series’ principal characters alongside Shun Oguri, Han Hyo-joo, and Jin Akanishi. Nakamura continued working even while receiving cancer treatment, making her final years notable not only for her illness but also for a career that continued to reach audiences in Japan and internationally.

What Is Rectal Cancer?

Rectal cancer is a cancer that develops in the tissues of the rectum, the final portion of the large intestine before the anus. It is generally grouped with colon cancer under the broader term colorectal cancer, although treatment can differ because of the anatomy of the pelvis and the risk of local recurrence. Rectal cancer treatment may involve surgery, chemotherapy, radiation therapy, chemoradiation, targeted therapy, immunotherapy, or a combination of approaches. Treatment is determined by factors including stage, tumor location, lymph-node involvement, molecular features, overall health, and whether cancer has spread to other organs.

The disease represents a substantial part of the colorectal cancer burden. The American Cancer Society estimates that approximately 49,990 new cases of rectal cancer will be diagnosed in the United States in 2026, including around 28,750 cases in men and 21,240 in women. Rectal cancer also now represents about 32% of colorectal cancer diagnoses, up from approximately 27% in the mid-2000s, according to the American Cancer Society’s 2026 colorectal cancer report.

Rectal Cancer Survival Depends Strongly on Stage

Rectal cancer outcomes vary substantially according to how far the disease has spread when it is first diagnosed. Based on U.S. SEER data for people diagnosed with rectal cancer from 2014 through 2020, the 5-year relative survival rates were:

• 90% for localized rectal cancer
• 74% for regional disease involving nearby structures or lymph nodes
• 18% for distant-stage disease
• 67% across all stages combined

These statistics describe populations and cannot predict an individual person’s outcome. They also apply to the stage at initial diagnosis and should not be applied directly to cancer that subsequently recurs or progresses. Age, tumor biology, molecular alterations, overall health, response to therapy, and whether metastatic disease can be removed or otherwise treated can all influence prognosis.

How Often Does Rectal Cancer Come Back?

Even after treatment given with curative intent, rectal cancer can recur. Cancer may return locally in the pelvis or appear at distant sites, most commonly organs such as the liver or lungs. Recurrence risk varies considerably according to the original stage, lymph-node involvement, surgical margins, pathological characteristics, and response to treatment. A large population-based study using the Netherlands Cancer Registry examined patients with surgically treated stage II and III colon and rectal cancer. Among patients with rectal cancer, the 5-year cumulative incidence of recurrence was:

• 23.4% for stage II rectal cancer
• 32.8% for stage III rectal cancer

The researchers found that distant recurrence was particularly important among patients with rectal cancer. These numbers should not be interpreted as the recurrence risk for every person with rectal cancer. Patients with earlier-stage disease may have substantially lower risk, while individual tumor characteristics can raise or lower the likelihood of recurrence. Modern surgical techniques have also improved local control. The National Cancer Institute notes that appropriately performed mesorectal excision has been associated with reported local failure rates of approximately 4% to 8% in selected series.

When rectal cancer does recur, the American Cancer Society notes that recurrence often occurs within the first two to three years after surgery, although cancer can also return considerably later. This is one reason ongoing surveillance after treatment can remain important.

Remission Does Not Always Mean Cancer Cannot Return

Cancer remission means that the signs and symptoms of cancer have decreased or disappeared. It does not always mean that the possibility of recurrence has been permanently eliminated. Follow-up after rectal cancer treatment may include clinical examinations, colonoscopy, imaging, and blood tests such as carcinoembryonic antigen, or CEA, depending on the patient’s original stage and treatment.

Surveillance is intended partly to detect recurrent disease when additional treatment may still be possible. In Nakamura’s case, her agency said she continued undergoing examinations after her earlier cancer went into remission. Cancer was then identified again years later. However, because the type of her original cancer was never disclosed, it would be inappropriate to assume that this represented recurrence of the same rectal cancer.

Colorectal Cancer Is Increasing Among Younger Adults

Nakamura was 44 when she died, drawing attention to a broader trend that has become increasingly important in oncology. Although colorectal cancer remains more common at older ages, incidence has been rising among younger adults. According to the American Cancer Society, colorectal cancer incidence among people younger than 50 increased by approximately 2.9% per year between 2013 and 2022. The shift is particularly striking for rectal cancer.

Among Americans younger than 50, rectal cancer incidence has nearly doubled since 1998, increasing from approximately 3.6 cases per 100,000 people to 6.6 per 100,000. The American Cancer Society also reports that 45% of new colorectal cancer diagnoses now occur in people younger than 65, compared with only 27% in 1995. Among patients younger than 50, approximately three in four colorectal cancers are diagnosed at regional or distant stages, and 27% are already distant-stage disease. The reasons for increasing early-onset colorectal cancer remain under investigation, and a young person’s gastrointestinal symptoms are still much more likely to have a non-cancerous cause. But age alone should not be used to dismiss persistent warning signs.

What Are the Warning Signs of Rectal Cancer?

Rectal cancer can sometimes develop without obvious early symptoms. When symptoms do occur, they may include rectal bleeding or blood in the stool, persistent diarrhea or constipation, a lasting change in bowel habits, a feeling that the bowel has not emptied completely, narrower or differently shaped stools, ongoing abdominal pain, cramping or bloating, unexplained weight loss, changes in appetite, and persistent fatigue.

The National Cancer Institute emphasizes that these symptoms can also occur with many non-cancerous conditions. Their presence does not mean that a person has cancer, but persistent or unexplained symptoms should be medically evaluated.

Why Can Bowel Obstruction Occur in Rectal Cancer?

Nakamura experienced intestinal obstruction during the later period of her illness. A bowel obstruction occurs when the normal movement of intestinal contents is partially or completely blocked. In someone with cancer, possible causes can include tumor growth, recurrent or metastatic disease, scar tissue following surgery, or other treatment-related complications. The National Cancer Institute lists intestinal obstruction among possible clinical features of rectal cancer. Symptoms may include severe or worsening abdominal pain, abdominal swelling, vomiting, constipation, and inability to pass gas or stool. A suspected bowel obstruction requires urgent medical evaluation.

What We Do Not Know About Yuri Nakamura’s Cancer

Several important clinical details about Nakamura’s illness were never made public. Her agency did not disclose her original cancer type from approximately 13 years earlier, the precise stage of her rectal cancer, molecular biomarkers, the location of her metastases, or the full chemotherapy, radiation, surgical, or other treatment regimens she received. Those details can significantly affect both treatment and prognosis. It would therefore be inappropriate to use population statistics to explain precisely why Nakamura’s cancer progressed or to suggest how another treatment might have changed her outcome.

Rectal Cancer Prognosis in South Korea

Rectal cancer outcomes in South Korea have improved considerably over time. An analysis of 326,712 colorectal cancer cases from the Korea Central Cancer Registry found that the 5-year relative survival rate for rectal cancer increased from 57.7% in 1996–2000 to 74.6% in 2011–2015. For localized rectal cancer diagnosed in 2011–2015, 5-year relative survival reached approximately 93.4%. More recent Korean national cancer statistics for colon and rectal cancer combined show how strongly prognosis depends on stage. Among patients diagnosed in 2019–2023, 5-year observed survival was approximately 87.7% for localized disease, 73.4% for regional disease, and 18.8% for distant metastatic disease.

Photo: Depositphotos

Rectal cancer also remains a major cancer burden in South Korea. In 2023, 15,507 rectal and rectosigmoid cancers were diagnosed, accounting for 5.4% of all newly diagnosed cancers in the country. These population statistics should not be used to estimate Yuri Nakamura’s individual prognosis, because her exact stage, sites of metastasis, biomarkers, and treatment regimen were not publicly disclosed.

Yuri Nakamura’s Story and the Broader Message

Yuri Nakamura continued working through years in which cancer was part of her private life, building a career that eventually reached audiences far beyond Japan. Her death at 44 also highlights several realities of modern colorectal cancer care: younger adults can develop the disease, metastatic rectal cancer remains difficult to treat, and cancer can return even after a period of remission. At the same time, her individual medical history should not be treated as representative of every patient with rectal cancer.

For localized rectal cancer, 5-year relative survival is approximately 90%, while outcomes become substantially poorer once disease has spread to distant organs. Recurrence risk likewise varies considerably according to the original stage and tumor characteristics. Persistent rectal bleeding, unexplained changes in bowel habits, unexplained weight loss, anemia, fatigue, or ongoing abdominal symptoms deserve medical attention regardless of age.

Nakamura’s story is therefore not only the story of an actress lost at 44. It is also a reminder of the importance of symptom awareness, long-term follow-up, evidence-based treatment, and continued research into colorectal cancer in younger adults.

You Can Also Read Ken Watanabe Cancer Journey: From AML and Early Gastric Cancer to an Inspiring Return to the Screen by OncoDaily

Written by Aharon Tsaturyan, MD, Editor at OncoDaily Intelligence Unit